Keurig Dr Pepper 株価情報 (NASDAQ: KDP)

最新ニュース Keurig Dr Pepper (NASDAQ:KDP) 株価情報

Keurig Dr Pepper

Dr Pepper Snapple Group

Keurig Dr Pepper was established in 2018 following a merger between Keurig Green Mountain Coffee and Dr Pepper Snapple. The company manufactures and distributes coffee systems (including coffee brewers and single-serve coffee pods) under the Keurig and Green Mountain brands, as well as ready-to-drink beverages including flavored (non-cola) sparkling soft drinks under well-known brands such as Dr Pepper, Snapple, and Canada Dry. The company controls production and route to market for its own brands through in-house manufacturing plants and distribution infrastructure and leverages these facilities to manufacture and distribute for third-party coffee and beverage brands via licensing and partnership agreements. The US and Canada make up 95% of revenue, with the rest from Mexico.

Keurig Dr Pepper Inc

WIIM

TZOO

Travelzoo shares are trading lower following worse-than-expected Q4 reported financial results.

Keybanc analyst Tim Rezvan initiates coverage on Infinity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INR#NYSE">INR</a>) with a Overweight rating and announces Price Target of $26.

News

Price Target

Initiation

Analyst Ratings

Morgan Stanley Market Vectors Rupee/USD ETN

Keybanc Initiates Coverage On Infinity with Overweight Rating, Announces Price Target of $26

ZONE

CleanCore Solutions shares are trading higher after the company announced it will acquire Sanzonate Europe.

Susquehanna analyst Christopher Stathoulopoulos maintains Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) with a Neutral and raises the price target from $247 to $250.

Susquehanna Maintains Neutral on Hilton Worldwide Holdings, Raises Price Target to $250

CJET

Chijet Motor: Stock Purchase Agreement With Too Express Group & Holders of Too Express's Outstanding Capital Shares To Acquire 80% Of Equity Interests

General

SOUN

SoundHound AI Announces AI Platform For Restaurants

Tempus AI Inc Files For Offering Of Up To 4.84M Shares Of Class A Common Stock By The Selling Stockholder

TARS

Tarsus Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results.

Keybanc analyst Tim Rezvan downgrades Civitas Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>) from Overweight to Sector Weight.

Downgrades

CIVI

Keybanc Downgrades Civitas Resources to Sector Weight

Susquehanna analyst Christopher Stathoulopoulos maintains Wyndham Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WH#NYSE">WH</a>) with a Neutral and raises the price target from $80 to $110.

Susquehanna Maintains Neutral on Wyndham Hotels & Resorts, Raises Price Target to $110

Biotech

NLSP

NLS Pharmaceutics And Kadimastem Collaborated With iTolerance; Complete Pre-IND MEeting With FDA For Type 1 Diabetes Treatment

UCTT

Ultra Clean shares are trading lower after Needham cut its price target on the stock from $44 to $40.

Susquehanna analyst Christopher Stathoulopoulos maintains Hyatt Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) with a Neutral and raises the price target from $150 to $155.

Susquehanna Maintains Neutral on Hyatt Hotels, Raises Price Target to $155

Stephens &amp; Co. analyst Mike Scialla initiates coverage on Infinity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INR#NYSE">INR</a>) with a Overweight rating and announces Price Target of $30.

Stephens & Co. Initiates Coverage On Infinity with Overweight Rating, Announces Price Target of $30

ADIL

Adial Pharmaceuticals shares are trading higher after the company announced it received FDA feedback for its vitro bridging strategy of AD04 and will proceed to manufacture clinical supplies for its upcoming Phase 3 clinical trial.

On Tuesday, Thermo Fisher Scientific Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) agreed to acquire Solventum&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) Purification &amp; Filtration business for approximately $4.1 billion in cash.
Solventum&#8217;s Purification &amp; Filtration business provides purification and filtration technologies for the production of biologics, medical technologies and industrial applications.
The Solventum business operates globally, with sites in the Americas, Europe, the Middle East, Africa and the Asia-Pacific region. The company has approximately 2,500 employees.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43337781/thermo-fisher-q4-earnings-beat-estimates-margin-expands" rel="noreferrer noopener">Thermo Fisher Q4 Earnings Beat Estimates, Margin Expands</a>
In 2024, Solventum&#8217;s Purification &amp; Filtration business generated approximately $1 billion in revenue.
Solventum&#8217;s Purification &amp; Filtration business complements Thermo Fisher&#8217;s bioproduction business.
&#8220;The addition of Solventum&#8217;s business is an outstanding strategic fit with our company and will create significant value for our customers and shareholders,&#8221; said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher.
The transaction is expected to be completed by the end of 2025.
The Purification &amp; Filtration business will become part of Thermo Fisher&#8217;s Life Sciences Solutions segment and is expected to generate mid-to-high-single-digit organic growth. The application of the PPI Business System will enable strong margin expansion and meaningful synergy realization.
The transaction is expected to be dilutive to adjusted EPS&nbsp;by $0.06 in the first year of ownership.
Excluding financing costs, the transaction is expected to be accretive by $0.28 in that period.
Thermo Fisher expects to realize approximately $125 million of adjusted operating income from revenue and cost synergies by year five following the close.
Price Action: TMO stock closed at $535.55 on Monday. SOLV stock is up 1.93% at $77.75 during the premarket session on last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43938612/eli-lilly-expands-zepbound-vial-options-lowers-prices-for-25-mg-5-mg-doses" target="_blank" rel="noreferrer noopener">Eli Lilly Expands Zepbound Vial Options, Lowers Prices For 2.5 mg, 5 Mg Doses</a></li>
</ul>
Photo: Shutterstock

Large Cap

Health Care

SOLV

Thermo Fisher Bets Big On Bioproduction With Solventum's Unit Deal Worth $4.1 Billion

Susquehanna analyst Christopher Stathoulopoulos maintains Choice Hotels Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>) with a Neutral and raises the price target from $130 to $155.

Susquehanna Maintains Neutral on Choice Hotels Intl, Raises Price Target to $155

Micron Technology To Ship Samples Of 1-gamma DRAM Node-Based DDR5 Memory To Ecosystem Partners And Select Customers

CADL

Candel Therapeutics shares are trading higher after the company announced its final survival data from randomized controlled phase 2 clinical trial of CAN-2409 in non-metastatic pancreatic cancer.

Contracts

SPAI

Safe Pro And Kyiv Polytechnic Institute Enters Into Multi-Year MOU To Collaborate On Artificial Intelligence And Drone Technology

Offerings

Press Releases

Keurig Dr Pepper Announces Pricing of Secondary Offering of Common Stock by JAB

Keurig Dr Pepper Appoints Drew Panayiotou as Chief Marketing Officer, U.S. Refreshment Beverages

Keurig Dr Pepper to Participate in Morgan Stanley Global Consumer & Retail Conference

Dr Pepper® Announces the Winners of the 16th Annual Dr Pepper Tuition Giveaway

Dividends

Keurig Dr Pepper Declares Quarterly Dividend

Keurig Dr Pepper Evolves Executive Leadership Team in Support of Growth Strategy

Keurig Dr Pepper to Report Fourth Quarter 2024 Results and Host Conference Call

Keurig Dr Pepper Unveils Bold New Flavors Across Iconic U.S. Cold Beverages Portfolio

Earnings

Keurig Dr Pepper Reports Q4 and Full Year 2024 Results and Provides 2025 Outlook

Embotelladora Andina S.A. Common Stock

Celsius Holdings

The Vita Coco Company, Inc. - Common Stock

Vita Coco

Coca-Cola Consolidated, Inc. - Common Stock

Coca-Cola Consolidated

National Beverage

Fomento Economico Mexicano S.A.B. de C.V. Common Stock

Fomento Economico

Coca-Cola

Coca Cola Femsa S.A.B. de C.V. American Depositary Shares, each representing 10 Units (each Unit consists of 3 Series B Shares and 5 Series L Shares)

Comments

Keurig Dr Pepper

ニュース

最新ニュース Keurig Dr Pepper (NASDAQ:KDP) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル